Lienal polypeptide promotes NK cells to suppress PCa survival in vitro

Rao,Qun; Zhang,Huiping; Zhang,Cuantai; Zhuang,Qianyuan; Du,Guanghui; Wang,Shaogang; Ye,Zhangqun; Chen,Yuan

doi:10.3892/ol.2018.8632

Lienal polypeptide promotes NK cells to suppress PCa survival in vitro

Authors:
- Qun Rao
- Huiping Zhang
- Cuantai Zhang
- Qianyuan Zhuang
- Guanghui Du
- Shaogang Wang
- Zhangqun Ye
- Yuan Chen
View Affiliations

Affiliations: Department of Gynaecology and Obstetrics, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430030, P.R. China, Center of Reproductive Medicine, Institute of Family Planning Research, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430030, P.R. China, Department of Geriatrics, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430030, P.R. China, Department of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430030, P.R. China
Published online on: May 4, 2018 https://doi.org/10.3892/ol.2018.8632
Pages: 425-430

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

As an important component in the innate immune system, natural killer (NK) cells have been demonstrated to be clinically associated with prostate cancer (PCa) progression and castration resistance. Therefore, the development of novel agents that may enhance the cytotoxicity of NK cells possesses promising therapeutic applications. In the present study, lienal polypeptide (LP) solution was supplemented into a co‑culture system of NK and PCa cells, as it was previously demonstrated that LP are able to activate NK cells, which kill PCa cells based on an MTT cell viability assay. Mechanistic dissection demonstrated that LP enhanced androgen receptor degradation, which resulted in an upregulation of MHC class I polypeptide‑related sequence A (MICA) and MICB. In turn, the induced expression of MICA and MICB was able to further trigger NK cell activation, forming a positive loop between NK cells and PCa cells in the presence of LP solution.

View Figures

View References

1	Siegel RL, Miller KD and Jemal A: Cancer statistics, 2016. CA Cancer J Clin. 66:7–30. 2016. View Article : Google Scholar : PubMed/NCBI
2	Huggins C: Effect of orchiectomy and irradiation on cancer of the prostate. Ann Surg. 115:1192–1200. 1942. View Article : Google Scholar : PubMed/NCBI
3	Heinlein CA and Chang C: Androgen receptor in prostate cancer. Endocr Rev. 25:276–308. 2004. View Article : Google Scholar : PubMed/NCBI
4	Coutinho I, Day TK, Tilley WD and Selth LA: Androgen receptor signaling in castration-resistant prostate cancer: A lesson in persistence. Endocr Relat Cancer. 23:T179–T197. 2016. View Article : Google Scholar : PubMed/NCBI
5	Bishop JL, Davies A, Ketola K and Zoubeidi A: Regulation of tumor cell plasticity by the androgen receptor in prostate cancer. Endocr Relat Cancer. 22:R165–R182. 2015. View Article : Google Scholar : PubMed/NCBI
6	Kaarbø M, Klokk TI and Saatcioglu F: Androgen signaling and its interactions with other signaling pathways in prostate cancer. Bioessays. 29:1227–1238. 2007. View Article : Google Scholar : PubMed/NCBI
7	Efstathiou E, Titus M, Tsavachidou D, Tzelepi V, Wen S, Hoang A, Molina A, Chieffo N, Smith LA, Karlou M, et al: Effects of abiraterone acetate on androgen signaling in castrate-resistant prostate cancer in bone. J Clin Oncol. 30:637–643. 2012. View Article : Google Scholar : PubMed/NCBI
8	Vasaitis TS, Bruno RD and Njar VC: CYP17 inhibitors for prostate cancer therapy. J Steroid Biochem Mol Biol. 125:23–31. 2011. View Article : Google Scholar : PubMed/NCBI
9	Tran C, Ouk S, Clegg NJ, Chen Y, Watson PA, Arora V, Wongvipat J, Smith-Jones PM, Yoo D, Kwon A, et al: Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science. 324:787–790. 2009. View Article : Google Scholar : PubMed/NCBI
10	Scher HI, Fizazi K, Saad F, Taplin ME, Sternberg CN, Miller K, de Wit R, Mulders P, Chi KN, Shore ND, et al: Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med. 367:1187–1197. 2012. View Article : Google Scholar : PubMed/NCBI
11	Corn PG: The tumor microenvironment in prostate cancer: Elucidating molecular pathways for therapy development. Cancer Manag Res. 4:183–193. 2012. View Article : Google Scholar : PubMed/NCBI
12	Karlou M, Tzelepi V and Efstathiou E: Therapeutic targeting of the prostate cancer microenvironment. Nat Rev Urol. 7:494–509. 2010. View Article : Google Scholar : PubMed/NCBI
13	Pasero C, Gravis G, Granjeaud S, Guerin M, Thomassin-Piana J, Rocchi P, Salem N, Walz J, Moretta A and Olive D: Highly effective NK cells are associated with good prognosis in patients with metastatic prostate cancer. Oncotarget. 6:14360–14373. 2015. View Article : Google Scholar : PubMed/NCBI
14	Wang R, Jaw JJ, Stutzman NC, Zou Z and Sun PD: Natural killer cell-produced IFN-γ and TNF-α induce target cell cytolysis through up-regulation of ICAM-1. J Leukoc Biol. 91:299–309. 2012. View Article : Google Scholar : PubMed/NCBI
15	Guo Y, Hu Q, Sun C, Gu B, Xu K and Xia G: Postoperative renormalization of C-reactive protein with adjuvant lienal polypeptide and its association with tumour recurrence in T1 clear cell renal cell carcinoma. J Int Med Res. 44:620–626. 2016. View Article : Google Scholar : PubMed/NCBI
16	Brett A, Pandey S and Fraizer G: The Wilms' tumor gene (WT1) regulates E-cadherin expression and migration of prostate cancer cells. Mol Cancer. 12:32013. View Article : Google Scholar : PubMed/NCBI
17	Lin SJ, Chou FJ, Li L, Lin CY, Yeh S and Chang C: Natural killer cells suppress enzalutamide resistance and cell invasion in the castration resistant prostate cancer via targeting the androgen receptor splicing variant 7 (ARv7). Cancer Lett. 398:62–69. 2017. View Article : Google Scholar : PubMed/NCBI
18	Nausch N and Cerwenka A: NKG2D ligands in tumor immunity. Oncogene. 27:5944–5958. 2008. View Article : Google Scholar : PubMed/NCBI
19	Koivisto P, Kononen J, Palmberg C, Tammela T, Hyytinen E, Isola J, Trapman J, Cleutjens K, Noordzij A, Visakorpi T and Kallioniemi OP: Androgen receptor gene amplification: A possible molecular mechanism for androgen deprivation therapy failure in prostate cancer. Cancer Res. 57:314–319. 1997.PubMed/NCBI
20	Joseph JD, Lu N, Qian J, Sensintaffar J, Shao G, Brigham D, Moon M, Maneval EC, Chen I, Darimont B and Hager JH: A clinically relevant androgen receptor mutation confers resistance to second-generation antiandrogens enzalutamide and ARN-509. Cancer Discov. 3:1020–1029. 2013. View Article : Google Scholar : PubMed/NCBI
21	Dehm SM, Schmidt LJ, Heemers HV, Vessella RL and Tindall DJ: Splicing of a novel androgen receptor exon generates a constitutively active androgen receptor that mediates prostate cancer therapy resistance. Cancer Res. 68:5469–5477. 2008. View Article : Google Scholar : PubMed/NCBI
22	Wang R, Sun Y, Li L, Niu Y, Lin W, Lin C, Antonarakis ES, Luo J, Yeh S and Chang C: Preclinical study using malat1 small interfering RNA or androgen receptor splicing variant 7 degradation enhancer ASC-J9^®to suppress enzalutamide-resistant prostate cancer progression. Eur Urol. 72:835–844. 2017. View Article : Google Scholar : PubMed/NCBI
23	Wu JD, Higgins LM, Steinle A, Cosman D, Haugk K and Plymate SR: Prevalent expression of the immunostimulatory MHC class I chain-related molecule is counteracted by shedding in prostate cancer. J Clin Invest. 114:560–568. 2004. View Article : Google Scholar : PubMed/NCBI